Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

被引:33
|
作者
Bolte, Laura A. [1 ,2 ,3 ]
Lee, Karla A. [4 ]
Bjork, Johannes R. [1 ,2 ,3 ]
Leeming, Emily R. [4 ]
Campmans-Kuijpers, Marjo J. E. [1 ,2 ]
de Haan, Jacco J. [1 ,2 ,5 ]
Vila, Arnau Vich [1 ,2 ,3 ]
Maltez-Thomas, Andrew [6 ]
Segata, Nicola [6 ,7 ]
Board, Ruth [8 ]
Harries, Mark [9 ]
Lorigan, Paul [10 ]
de Vries, Elisabeth G. E. [2 ,5 ]
Nathan, Paul [11 ]
Fehrmann, Rudolf [2 ,5 ]
Bataille, Veronique [4 ,12 ]
Spector, Tim D. [4 ]
Hospers, Geke A. P. [2 ,5 ]
Weersma, Rinse K. [1 ,2 ]
机构
[1] Univ Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[2] Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Groningen, Dept Genet, Groningen, Netherlands
[4] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England
[5] Univ Groningen, Dept Med Oncol, Groningen, Netherlands
[6] Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy
[7] European Inst Oncol, IRCSS, Milan, Italy
[8] Lancashire Natl Hlth Serv NHS Fdn Trust, Royal Preston Hosp, Dept Med Oncol, Fulwood, England
[9] Guys & St Thomass NHS Trust, Guys Canc Ctr, Dept Med Oncol, London, England
[10] Christie NHS Fdn Trust, Dept Dermatol, Manchester, England
[11] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, England
[12] West Hertfordshire NHS Trust, Dept Dermatol, Watford, England
关键词
IMMUNOTHERAPY; QUALITY; CANCER;
D O I
10.1001/jamaoncol.2022.7753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, isa poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB.OBJECTIVE To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021.EXPOSURES Patients were treated with anti-programmed cell death 1 and anti-cytotoxic T lymphocyte-associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment.MAIN OUTCOMES AND MEASURES Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher.RESULTS There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54).CONCLUSIONS AND RELEVANCE This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB.
引用
收藏
页码:705 / 709
页数:5
相关论文
共 50 条
  • [31] Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors
    Che, Hebin
    Xiong, Qi
    Ma, Jinxia
    Chen, Shixue
    Wu, Huan
    Xu, Hongli
    Hou, Baicun
    BMC CANCER, 2022, 22 (01)
  • [32] Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors
    Hebin Che
    Qi Xiong
    Jinxia Ma
    Shixue Chen
    Huan Wu
    Hongli Xu
    Baicun Hou
    BMC Cancer, 22
  • [33] Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors
    Hou, Baicun
    Wang, Peng
    Liu, Tingting
    Chen, Shixue
    Li, Tao
    Zhang, Sujie
    Tao, Haitao
    Li, Xiaoyan
    Hu, Yi
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (05)
  • [34] Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors
    Angeles, Arkhjamil
    Sonke, Eric
    Thao Phuong Nguyen
    Bahl, Gaurav
    Poon, Vincent Isaac
    Bernstein, Vanessa
    Weppler, Alison Margaret
    Savage, Kerry J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
    Dravillas, Caroline E.
    Coleman, Samuel S.
    Hoyd, Rebecca
    Caryotakis, Griffin
    Denko, Louis
    Chan, Carlos H. F.
    Churchman, Michelle L.
    Denko, Nicholas
    Dodd, Rebecca D.
    Eljilany, Islam
    Hardikar, Sheetal
    Husain, Marium
    Ikeguchi, Alexandra P.
    Jin, Ning
    Ma, Qin
    McCarter, Martin D.
    Osman, Afaf E. G.
    Robinson, Lary A.
    Singer, Eric A.
    Tinoco, Gabriel
    Ulrich, Cornelia M.
    Zakharia, Yousef
    Spakowicz, Daniel
    Tarhini, Ahmad A.
    Tan, Aik Choon
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (08): : 1978 - 1990
  • [36] Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.
    Rapisuwon, Suthee
    Shoushtari, Alexander Noor
    Gottesdiener, Lee S.
    Johnson, Douglas Buckner
    Wang, Daniel Ying
    Graham, Garrett Thomas
    Goerlitz, David
    Berry, Deborah
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors
    Howell, Ashley, V
    Gebregziabher, Mulugeta
    Thiers, Bruce H.
    Graboyes, Evan M.
    Paulos, Chrystal M.
    Wrangle, John M.
    Hunt, Kelly J.
    Wallace, Kristin
    JOURNAL OF GERIATRIC ONCOLOGY, 2022, 13 (07) : 1003 - 1010
  • [38] A retrospective study on the long-term survival and incidence of metachronous malignancies in advanced melanoma patients treated with immune checkpoint blockade (ICB)
    Verschaeve, F.
    Vandelaer, N.
    Vander Mijnsbrugge, A-S.
    Tijtgat, J.
    Schwarze, J. K.
    Awada, G.
    Kessels, J.
    Aspeslagh, S.
    Cools, W.
    Rogiers, A.
    Neyns, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S933 - S933
  • [39] PREDICTORS OF RHEUMATIC TOXICITIES OF IMMUNE CHECKPOINT INHIBITORS AND CANCER OUTCOMES IN PATIENTS WITH ADVANCED MELANOMA
    Bruce, A.
    Menzies, A.
    Long, G.
    Fernandes, B.
    Joshua, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1818 - 1819
  • [40] Dietary Intervention in Melanoma Patients Treated with Immune Checkpoint
    Shaverdashvili, Khvaramze
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)